Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13063-8. doi: 10.1073/pnas.1002372107. Epub 2010 Jun 29.
Recent reports have suggested critical roles of myeloid cells in tumor invasion and metastasis, although these findings have not led to therapeutics. Using a mouse model for liver dissemination, we show that mouse and human colon cancer cells secrete CC-chemokine ligands CCL9 and CCL15, respectively, and recruit CD34(+) Gr-1(-) immature myeloid cells (iMCs). They express CCL9/15 receptor CCR1 and produce matrix metalloproteinases MMP2 and MMP9. Lack of the Ccr1, Mmp2, or Mmp9 gene in the host dramatically suppresses outgrowths of disseminated tumors in the liver. Importantly, CCR1 antagonist BL5923 blocks the iMC accumulation and metastatic colonization and significantly prolongs the survival of tumor-bearing mice. These results suggest that CCR1 antagonists can provide antimetastatic therapies for patients with disseminated colon cancer in the liver.
最近的报告表明,髓样细胞在肿瘤侵袭和转移中具有关键作用,尽管这些发现并未导致治疗方法的出现。我们使用一种用于肝脏扩散的小鼠模型,表明小鼠和人结肠癌细胞分别分泌 CC-趋化因子配体 CCL9 和 CCL15,并招募 CD34(+)Gr-1(-)幼稚髓样细胞(iMC)。它们表达 CCL9/15 受体 CCR1 并产生基质金属蛋白酶 MMP2 和 MMP9。宿主中 Ccr1、Mmp2 或 Mmp9 基因的缺失会显著抑制肝脏中播散性肿瘤的生长。重要的是,CCR1 拮抗剂 BL5923 可阻止 iMC 聚集和转移定植,并显著延长荷瘤小鼠的存活时间。这些结果表明,CCR1 拮抗剂可为肝内播散性结肠癌患者提供抗转移治疗。